Fujiwara T, Maeta H, Chida S, Morta T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55-59.
Hall SB. Venkitaraman AR, Whitsett JA, Holm B, Notter RH. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis 1992; 145: 24-30.
Johansson J, Curstedt T, Robertson B. Synthetic protein analogues in artificial surfactants. Acta Pediatr 1996; 85: 642- 646.
Cochrane CG, Revak SD, Merritt T A, Heldt GP, Hallman M, Cunningham MD, et al. The efficacy and safety of KL4 surfactant in preterm infants with respiratory distress syndrome. Am
Care Med 1996; 153: 404-410.
SolI RF, McQueen MC Respiratory distress syndrome. In: Effective Care of the Newborn Infant. Eds. Sinclair JC, Bracken MB. Oxford: Oxford University Press, 1992; pp 325-358.
Jobe AH. Pulmonary surfactant therapy. New Engl
Med 1993; 328: 861-868.
Horbar JD, Wright EC, Onstad L, and members of the National Institute of Child Health and Human Development Neonatal Research Network. Decreasing mortality associated with the introduction of surfactant therapy: An observational study of neonates weighing 601-1300 grams at birth. Pediatrics 1993; 92: 191- 196.
Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500g. N'Engl
Med 1994; 330: 1476-1480.
McCord FB, Curstedt T, Halliday HL, McClure G, Reid MM, Robertson B. Surfactant treatment and incidence of intra-ventricular hemorrhage in severe respiratory distress syndrome. Arch Dis Child 1988; 63: 10-16.
Fujiwara T, Konishi M, Chida S, Watabe Y, Abe T. Surfactant replacement therapy with a single postventilatory dose of a re-constituted bovine surfactant in preterm neonates with respiratory distress syndrome: Final analysis of a multicenter,
double-blind, randomized that and comparison with similar trials. Pediatrics 1990;86:753-764.
Horbar JD, SolI RF, Schachinger H,
Kewitz G, Versmold HT, Lindner W, et al. AEuropean multicentre randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome. Eur
Pediatr 1990; 149: 416- 423.
Hellstrom-Westas L, Bell AH, Skov L, Greisen G, Svennigson NW. Cerebroelectrical depression following surfactant treatment in preterm neonates. Pediatrics 1992; 89: 643-647.
Lundstrom KE, Greison G. Changes in EEG, systemic circulation and blood gas parameters following two or six aliquots of porcine surfactant. Acta Paediatr 1996; 85: 708-712.
Cowan F, Whitelaw A, Wertheim D, Silverman M. Cerebral blood flow velocity changes after rapid administration of surfactant. Arch Dis Child 1991; 66: 1105- 1109.
Gunkel JH, Banks PLC. Surfactant therapy and intracranial hemorrhage: Review of the literature and results of new analyses. Pediatrics 1993; 92: 775-786.
Edwards AD, McCormick DC, Roth SC, Elwell CE, Peebles DM, Cope M, et al. Cerebral hemodynamic effects of treatment with modified natural surfactant investigated by near infrared spectorscopy. Pediatr Res 1992; 32: 532-536.
Tubman TR, Rankin SJ, Halliday HL, Johnston S5. Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity. Bioi Neonate 1992; 61(Suppll:): 54-58.
Repka MX, Hardy RJ, Phelps DL, Summers CG. Surfactant prophylaxis and retinopathy of prematurity. Arch Ophthalmol1993; 111: 618-620.
Termote J, Schalij-Delfos NE, Cats BP, Wittebol-Post D, Hoogervorst BR, Browers HAA. Less severe retinopathy of prematurity induced by surfactant re- placement therapy. Acta Paediatr 1996; 85: 1491-1496.
Halliday HL, Mcclure G, Reid McC. Growth and development two years after artificial surfactant replacement at birth. Early Hum Dev 1986; 113: 323-327.
Vaucher YE, Merritt TA, Hallman M, Jarvenpaa A, Telsey AM, Jones BL. Nuerodevelopmental and respiratory outcome in early childhood after human surfactant treatment. Am
Dis Child 1988; 142: 927-930.
Dunn MS, Shennan AT, Hoskins EM, Lennox K, Enhorning G. Two-year follow-up of
infants enrolled in a randomized trial of surfactant replacement therapy for prevention of neonatal respiratory distress syndrome. Pediatrics 1988; 82: 543-547.
Morley CJ, Morley R. Follow up of premature babies treated with artificial surfactant (ALEC). Arch Dis Child 1990; 65: 667-669.
Ware J, Taeusch HR, SolI RF, McCormick MC Health and developmental outcomes of a surfactant controlled trial: Follow-up at 2 years. Pediatrics 1990; 85: 1103-1107.
Robertson B, Curstedt T, Tubman R, Strayer D, Berggren P, Kok J, et al. A 2- year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Collaborative
European Multicentre Study Group. Eur
Pediatr 1992;151: 372-376.
Walti H, Boule M, Moriette G, Relier JP. Pulmonary functional outcome at one year of age in infants treated with natural porcine surfactant at birth. BioI Neonate 1992; 61 (Suppl 1): 48-53.
Couser RJ, Ferrara TB, Wheller W, McNamara J, Falde B, Johnson K, Hoekstra RE. Pulmonary follow-up 2.5 years after a randomized, controlled multiple dose bovine surfactant study of preterm newborn infants. Pediatr Pulmonol1993; 15: 163-167.
Abbasi S, Bhutani VK, Gerdes JS. Long-term pulmonary consequences of respiratory distress syndrome in preterm infants
treated with exogenous surfactant.
Pediatr 1993; 122: 446-452.
Survanta Multidose Study Group. Two- year follow-up of infants treated for neonatal respiratory distress syndrome with
J Pediatr 1994; 124: 962-
Corbet A, Long W, Schumacher R, Gerdes J, Cotton R: Double-blind developmental evaluation at
1-year corrected age of 597 premature infants with birth weights from 500 to 1350 grams enrolled in three placebo-controlled trials of prophylactic
Pediatr 1995; 126:
Walther FJ, Mullett M, Schumacher R.,
Sundell H, Easa D, Long W. One-year follow-up of 66 premature infants weighing 500 to 699 grams treated with a single dose of synthetic surfactant or air placebo
at birth: Results of a double-blind trial.
J Pediatr 1995; 126: S13-S19.
Sell M, Cotton R, Hirata T, Gurthie R, LeBlanc M, Mammel M, Long W. One-year follow-up of 273 infants with birth weights of 700 to 1100 grams after pro-phylactic treatment of respiratory distress syndrome with synthetic surfactant or air
Pediatr 1995; 126: S20-S25.
Gerdes J, Gerdes M, Beaumont E, Cook L, Dhanireddy R, Kopleman A, et al. Health and neurodevelopmental outcome at 1- year adjusted age in 508 infants weighing 700 to 1100 grams who received prophylaxis with one versus three doses of synthetic surfactants.
Pediatr 1995; 126: S26-
Kraybill EN, Bose C, Corbet A, Garcia-Prats J, Asbill D, Edwards K, Long W. Double-blind evaluation of developmental
and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo.
Pediatr 1995; 126: S33-542.
Courtney SE, Long W, McMillan D, Walter D, Thompson T, Sauve R, et al. Double-blind
1-year follow-up of 1540 infants with respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air in four
Pediatr 1995; 126: S43-S52.
Casiro 0, Bingham W, MacMurray B, Whitfield M, Saigal S, Vincer M, Long W. One-year follow-up of 89 infants with birth weights of 500 to 749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo.
Pediatr 1995; 126: S53-S60.
Saigal S, Robertson C, Sarikaran K, Bingham W, Casiro 0, MacMurray B, et al.
One-year outcome in 232 premature infants with birth weights of 750 to 1249
grams and respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air placebo.
Pediatr 1995; 126: 561-567.
Gong A, Aanday E, Boros S, Bucciarelli R, Burchfielf D, Zucker J, Long W.
One-year follow-up evaluation of260 premature infants with respiratory distress syndrome and birth weights of 700 to 1350 grams randomized to two rescue doses of synthetic surfactant or air placebo.
Pediatr 1995; 126: 568-574.
Sauve R, Long W, Vincer M, Bard H, Derleth , Stavenson D, et al. Outcome
at 1-year adjusted age of 957 infants weighing more than 1250 grams with respiratory
distress syndrome randomized to receive synthetic surfactant or air placebo.
Pediatr 1995; 126: 575-580.
Zola EM, Gunkel JH, Chan RK, Urn MO, Knox I, Feldman BH, et al. Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome.
Merritt TA, Kheiter A, Cochrane CG. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Pediatr Res 1995; 38: 211-217.
Broadbent R, Fok TF, Dolovich M, Watts 1, Coates G, Bowen B, Kirpalani H. Chest position and pulmonary deposition of surfactant in sufactant depleted rabbits. Arch Dis Child 1995; 72: F84~F89.
Saliba E, Nashashibi M, Vaillant M-C, Nasr C, Laugier J. Instillation rate effects of Exosurf on cerebral and cardiovascular hemodynamics in preterm neonates. Arch Dis Child 1994; 71: FI74-FI78.
44. Skinner J. The effects of surfactant on hemodynamics in hyaline membrane disease. Arch Dis Child 1997; 76: F67-F69.
Sitler CG, Turnage CS, McFadden BE, Smith EO, Adams JM. Pump administration of exogenous surfactant: Effects on
oxygenation, heart rate, and chest wall
movement of premature infants.
Perinatol1993; 13: 197-2000.
Ueda T, Ikegami M, Rider ED, Jobe AH. Distribution of surfactant and ventilation in surfactant-treated preterrn lambs.
Appl Physiol1994; 76: 45-55.
Henry MD, Rebello CM, Ikegami M, Jobe AH, Langenbaack EG, Davis JM. Ultra-sonic nebulized in comparison with instilled surfactant treatment of preterm lambs. Am
J Respir Crit Care Med 1996; 154: 366-375.
Cosmi EV, La Torre R, Di Iorie R, Anceschi MM. Surfactant administration to the human fetus in utero: A new approach to prevention of neonatal respiratory distress syndrome.
1996; 24: 191-193.
Dunn MS, Shennan AT, Zayack D, Possmayer F. Bovine surfactant replacement
therapy in neonates of less than 30 weeks' gestation: A randomized
controlled trial of prophylaxis versus treatment. Pediatrics 1991; 87: 377-386.
Kendig JW, Notter RH, Cox C, Reubens LJ, Davis JM, Maniscalco WM, et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. New Engl
Med 1991; 324; 865-871.
Merritt T A, Hallman M, Berry C, Pohjavuori M, Edwards DK, Jaaskelainen J, et al. Randomized, placebo- controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity.
Pediatr 1991; 118: 581-594.
Konishi M, Fujiwara T, Chida 5, Maeta H, Shimada S, Kasai T, et al. A prospective, randomized trial of early versus late ad- ministration of a single dose of surfac- tant-RA. Early Hum Dev 1992; 29: 275- 282.
Egberts J, de Winter JP, Sedin G, de Kleine MJK, Broberger U, can Bel F, et al. Comparison of prophylaxis and rescue.
treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized.. trial. Pediatrics 1993; 92: 768-774. Kattwinkel J, Bloom BT, Delmore P, Davis CL, Farrell E, Friss H, et
al. Prophylactic administration of calf lung surfactant
extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gesta- tion. Pediatrics 1993; 92: 90-98.
Walti H, Paris-Llado J, Breart G, Couchard M, and the French Collabora- tive Multicentre
Study Group. Porcine surfactant replacement therapy in newborns of
25-31 weeks' gestation: A randomized, multicentre trial of prophylaxis versus rescue with multiple low doses. Acta Paediatr 1995; 84: 913-921.
Bevilacqua G, Parmigiani S, Robertson B and the Italian Collaborative Multicenter Group. Prophylaxis of respiratory diestress syndrome by treatment with modified porcine surfactant at birth: A multicenter prospective randomized trial.
Perinat Med 1996; 24: 609-620.
57. Dunn MS. Surfactant replacement therapy: Prophylaxis or
treatment? Pediatrics 1993; 92: 148-150.
Roll RF. Surfactant therapy in the USA: Trials and current routines. BioI Neonate 1997;71: 1-7.
Morley CJ. Systematic review of prophylactic vs rescue surfactant. Arch Dis Child 1997; 77: F70-F74.
Vaucher YE, Harker L, Merritt TA, Hallman M, Gist K, Bejar R, et al. Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: A randomized, placebo-con-
trolled trial of human surfactant.
1993; 122: 126-132.
The OSIRIS Collaborative Group. Early versus delayed neonatal administration of synthetic surfactant-the judgement of OSIRIS. Lancet 1992; 340: 1363-1369.
Verder H, Robertson B, Greisen G, Ebbesen T, Albertsen P, Lundstrom K, et
al. Surfactant therapy and nasal continuous positive airway
pressure for newborns with respiratory distress syndrome. N Engl
Med 1994; 331: 1051-1055.
Alba J, Agrawal R, Hegyi T, Hiatt 1M. Efficacy of surfactant therapy in infants managed with CP AP. Pediatr Pulmonol 1995; 20: 172-176.
Ikegami M, Adams FH, Towers B, Osher AB. The quantity of natural surfactant necessary to prevent the respiratory distress syndrome in premature lambs. Pediatr Res 1980; 14: 1082-1085.
Konishi M, Fujiwara T, Naito T, Takeuchi Y, Ogawa Y, Inukai K, et al. Surfactant replacement therapy if). neonatal respiratory distress syndrome. A multicentre,
randomized clinical trial: Comparison of high-versus low-dose surfactant T A. Eur
Pediatr 1988; 147: 20-25.
Gortner L, Pohlandt F, Bartmann P. High-dose versus low-dose bovine surfactant treatment in very prematur infants. Acta Paediatr 1994; 83: 135-141.
Jobe AH, Ikegami M, Seidner SR, Pettenazzo A, Ruffini L. Surfactant phosphotidylcholine metabolism and surfactant function in preterm ventilated lambs. Am Rev Respir Dis 1989; 139: 352- 359.
Fuchimukai T, Fujiwara T, Takahashi A, Enhorning G. Artificial pulmonary surfactant inhibited by proteins.
Appl Physiol1987; 62: 429-437.
Hallman M, Merritt TA, Akino T, Bry K. Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid: Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. Am Rev Respir Dis 1991; 144: 1376-1384.
Dunn MS, Shennan AT, Possmayer F. Single-versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome. Pediatrics. 1990; 86: 564-571.
Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller , et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: Single versus multiple doses of Curosurf. Pediatrics 1992; 89: 13-20.
Corbet A, Gerdes J, Long W, Avila E, Puri A, Rosenberg A, et a/.
Double-blind, randomized trial of one versus three prophylactic doses of synthetic surfactant in 826 neonates weighing 700 to 1100 grams: Effects on mortality rate.
Pediatr 1995; 126: 969-978.
Easa D, Pelke S, Nakamura KT, Barrett J, Balaraman V, Loo SWH, et al. Exosurf treatment investigational new drug phase: Effect of an individualized third dose in infants with respiratory distress syndrome. Pediatr Pulmonol1992; 14: 16- 22.
Cotton RB, Olsson T, Law AB, Parker RA, Lindstrom DP, Siiberberg AR, et al. The physiologic effects of surfactant treatment on gas exchange in newborn premature infants with hyaline membrane disease. Pediatr Res 1993; 34: 495-501.
Goldsmith LS, Greenspan JS, Rubenstein SD, Wolfson MR, Shaffer, TH. Immediate improvement in lung volume after exogenous surfactant: alveolar recruitment versus increased distention.
Pediatr 1991; 119: 424-428.
Svenningsen NW, Bjorklund L, Vilstrup C, Werner O. Lung mechanics (FRC and static pressure-volume diagram) after en- dotrachealsurfactant instillation: preliminary observations. BioI Neonate 1992; 61 (Suppl
Davis JM, Veness-Meehan K, Notter RH, Bhutani VK, Kendig JW, Shapiro. Changes in pulmonary mechanics after the administration of surfactant to infants with respiratory distress syndrome. New Engl
Med 1988; 319: 476-479.
Couser RJ, Ferrara TB, Ebert J, Hoekstra RE, Fangman JJ. Effects of exogenous surfactant therapy ondynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease.
Pediatr 1990; 116: 119-124.
Kelly E, Bryan H, Possmayer F, Frndova H, Bryan C. Compliance of the respiratory system in newborn infants pre-and postsurfactant replacement, therapy. Pediatr Pulmonol1993; 15: 225-230.
de Winter JP, Merth IT, van Bel F, Egberts J, Brand R, Quanjer PhH. Changes of respiratory
system mechanics in ventilated lungs of preterm infants with two
different schedules of surfactant treatment. Pediatr Res 1994; 35: 541-549.
Baraldi E, Pettenazzo A, Filippone M, Magagnin GP, Saia OS, Zacchello. Rapid improvement of static compliance after surfactant treatment in preterm infants with respiratory distress syndrome. Pediatr Pulmonol1993; 15: 157-162.
Pfenninger J, Aebi C, Bachmann D, Wagner BP. Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (Exosurf). Pediatr Pulmonol 1992; 14: 10-15.
Armsby DH, Bellon G, Carlisle K, Rector D, Baldwin R, Long W, et a/. Delayed compliance increase in infants with respiratory distress syndrome following synthetic surfactant. Pediatr Pulmonol 1992; 14: 206-213.
Corcoran JD, Berggren P, Sun B, Halliday HL, Robertson B, Curstedt T. Comparison of surface properties and physiological effects of a synthetic and a natural surfactant in preterm rabbits. Arch Dis Child 1994; 71: F165-169.
Hamdan AH, Shaw NJ. Changes in pulmonary artery' pressure in infants with respiratory distress syndrome following treatment with Exosurf. Arch Dis Child 1995;72:F176-179.
Milner AD. How does exogeneous surfactant work? Arch Dis Child 1993; 68: 253- 254.
Kaapa P, Seppanen M, Kero P, Saraste M. Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome.
J Pediatr 1993; 123: 115-119.
Shimada S, Kasai T, Konishi M, Fujiwara T. Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant.
Pediatr 1994; 125: 270-277.
Garland J, Buck R, Weinberg M. Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus
arteriosus: A retrospective cohort study. Pediatrics 1994; 94: 719-723.
van Houten J, Long W, Mullet M, Finer N, Derieth D, McMurray B, et al. Pulmonary hemorrhage in premature infants after treatment with synthetic surfactant: An autopsy evaluation.
Pediatr 1992; 120: 540-544.
Amato M, Huppi P, Markus D. Prevention of symptomatic patent ductus arteriosus with ethamsylate in babies treated
with exogenous surfactant.
1993; 13: 2-7.
Horbar JD, Wright LL, SolI RF, Wright EC, Fanaroff AA, Korones SB, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome.
J Pediatr 1993; 123: 757-766.
Vermont-Oxford Neonatal Network. A multicentet, randomized trial comparing
synthetic surfactant with modified bovine surfactant extract in
the treatment of neo- natal respiratory distress syndrome. Pediatrics 1996; 97: 1-6.
Hudak M, Farrell EE, Rosenberg AA, Jung AL. Auten RL, Durand DJ, et al. A multicenter
randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory
Pediatr 1996; 128: 396-406.
Halliday HL. Synthetic or natural surfactants. Acta Paediatr 1997; 86: 233-237.
96. Halliday HL. Clinical trials of surfactant replacement in Europe. BioI Neonate 1997; 71 (Suppll): 8-12.
Speer CP, Gefeller O, Groneck P. Randomized clinical trial of two treatment regimens of natural surfactant preparations in neonatal distress syndrome. Arch Dis Child 1995; 72: F8-F13.
98. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997; 100: 31-38.
Holm BA, Hudak ML, Hudak ML, Hudak BB, Ferguson WH, Egan EA. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs. Am Rev Respir Dis 1992; 145: 999-1004.
100. Charon A, Taeusch HW, Fitzgibbon C, Smith GB, Treves ST, Phelps DS. Factors
associated with surfactant treatment response in infants with severe respiratory distress syndrome. Pediatrics 1989; 83: 348-354.
101. Collaborative European Multicentre Study Group. Factors influencing the
clinical response to surfactant replacement therapy in babies with severe respiratory distress syndrome. Eur
102. Konishi M, Chida S, Simada S, Kasai T, Murakami Y, Cho K, et al. Surfactant replacement therapy in premature babies with respiratory distress syndrome: Factors affecting the response to surfactant and comparison of outcome from 1982-86 and 1987-91. Acta Paediatr Jpn 1992; 34: 617-630.
103. Hallman M, Merritt T A, Bry K, Berry C.
Association between neonatal practices and efficacy of exogenous human surfactant: Results of bicenter randomized trial. Pediatrics 1993; 91: 552-560.
104. Hamvas A, Devine T, Cole FS. Surfactant therapy identifies infants at risk for pulmonary mortality. Am
Dis Child 1993; 147: 665-668.
105. Ferrara TB, Hoekstra RE, Couser RJ, Jack- son JC, Anderson CL, Myers TF, Raye JR. Effects of surfactant therapy on outcome of infants with birth weights of 600 to 750 grams.
Pediatr 1991; 119: 455-457.
106. Ferrara TB, Hoekstra RE, Couser RJ, Gaziano EP, Calvin SE, Payne NR, Fangman
Survival and follow-up of in- fants born at 23 to 26 weeks of gestational age: effects of surfactant therapy.
Pediatr' 1994;124: 119-124.
107. Segerer H, Stevens P, Schadow B, Maier R, Kattner E, Schwarz H, et al.
Surfactant substitution in ventilated very low birth weight
infants: Factors related to response types. Pediter Res 1991; 30: 591- 596.
108. Kuint J, Reichman B, Neumann L, Shinwell ES. Prognostic value of the immediate response to surfactant. Arch Dis Child 1994; 71: F170-F173.
109. Maniscalco WM, Kendig JW, Shapiro DL. Surfactant replacement therapy:
impact on hospital charges for premature infants with respiratory
distress syndrome. Pediatrics 1989; 83: 1-6.
110. Tubman TRJ, Halliday HL, Normand C. Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: A randomized controlled trial. Brit Med
1990; 301: 842-845.
111. Mugford M, Piercy J, Chalmers 1. Cost implications of different approaches
to the prevention of respiratory distress syndrome. Arch Dis Child 1991; 66: 757-764.
112. Farrell EE, Silver RK, Kimberlin LV, Wolf ES, Dusik JM. Impact of antenatal dexamethasone administration on respiratory distress syndrome in surfactant-
treated infants. Am
1989; 161: 628-633.
113. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am
Gyneco11993; 168: 508-513.
114. White A, Marcucci G, Andrews E, Edwards K, Long W. Antenatal steroids and neonatal outcomes in controlled clinical trials of surfactant replacement. Am
J Obstet Gyneco11995; 173: 286-290.
115. Andrews EB, Marcucci G, White A, Long W. Associations between use of antenatal corticostewids and neonatal outcomes within the Exosurf neonatal treatment in-
vestigational new drug program. Am
Obstet Gynecol1995; 173: 290-295.
116. Leviton A, Kurban KC, Pagano M, Allred EN, Van Marter L. Antenatal corticosteroids appear to reduce the risk of postnatal germinal matrix hemorrhage in intubated low birth weight newborns. Pediatrics 1993;91:1083-1088.
117. Robertson B. Corticosteroids and surfactant for prevention of neonatal RDS. Ann Med 1993; 25: 285-288.
118. Egberts J. Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants to less than 30 weeks of gestation. BioI Neonate 1992; 61 (Suppl1): 59-65.
119. Walther FJ, Kuipers 1M, Gidding CEM, Willebrand D, Buchholtz RTF, Bevers EM. A comparison of high-frequency oscillation superimposed onto back up mechanical ventilation and conventional mechanical ventilation on the distribution of exogenous surfactant in premature lambs.
Pediatr Res 1987;
120. Jackson JC, Truog WE, Standaert TA, Murphy JH, Juul SE, Chi EY, et al. Reduction in lung jury after combined surfactant and high-frequency ventilation. Am
Respir CritCare Med 1994; 150:
121. Sun B, Curstedt T, Robertson B. Surfactant inhibition in experimental meconium aspiration syndrome. Acta Paediatr 1993; 82: 182-189.
122. Sun B. Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration. Am
Respir Crit Care Med 1996; 154: 764- 770.
123. Halliday HL, Speer CP, Robertson B. Treatment of severe meconium aspiration syndrome with porcine surfactant. Eur
Pediatr 1996; 155: 1047-1051.
124. Findley RD, Taeusch HW, Walther FJ.
Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97:48-52.
125. Ibara S, Ikenoue T, Murata Y, Sakamoto H, Saito T, Nakamura Y, et al:
Management of severe meconium aspiration syndrome by tracheobronchial lavage and replacement of Surfactant- T A. Acta
Paediatr Japon 1995; 37: 64-67.
126. Fetter WPF, Baerts W, Bos AP, van Lingen RA. Surfactant replacement therapy
in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr 1995; 84: 14-16.